ONGOING STUDIES

• IELSG4925 November 2021
  IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
• IELSG449 December 2020
  IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
• IELSG47 Study4 October 2019
  MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

LATEST NEWSLETTER

• Newsletter Number 5330 November 2021

  Click here to open the pdf file – Click here to read the newsletter in HTML

• Newsletter Number 5224 February 2020
  Click here to open pdf file

PUBLICATIONS

• Genetic and phenotypic attributes of splenic marginal zone lymphoma14 February 2022
  Reference Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386. Link Author(s) Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, […]
• MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial1 February 2021
  Lancet Haematol 2021; 8: e110-21. Authors: Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JCE, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K, for the International Extranodal Lymphoma Study Group (IELSG)